martedì, 16 aprile 2024
Medinews
9 Novembre 2017

FDA Approves Frontline Alectinib for ALK-Positive NSCLC

November 6, 2017 – The FDA has approved alectinib for the frontline treatment of patients with ALK-positive metastatic non–small cell lung cancer (NSCLC), according to Genentech (Roche), the manufacturer of the second-generation ALK inhibitor. The frontline approval is primarily based on findings from the phase III ALEX study. Compared with crizotinib, alectinib improved progression-free survival (PFS) by 47% (hazard ratio [HR], 0.53; 95% CI, 0.38-0.73; P <.0001) in the ... (leggi tutto)

TORNA INDIETRO